RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

Impact of FLT3 inhibitors on the outcomes of FLT3-ITD-positive acute myeloid leukemia following allogeneic hematopoietic stem cell transplant: A systematic review and meta-analysis. This is an ASCO ...

The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...

SENTI-202 targets CD33 or FLT3, sparing EMCN, enhancing precision in treating hematologic malignancies like AML. Preliminary data shows high efficacy, with significant composite complete remission ...

The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...

Hydroxyurea vs. hypomethylating vs. other agents in chronic myelomonocytic leukemia: A retrospective inspection of treatment strategies among 457 Mayo Clinic patients. This is an ASCO Meeting Abstract ...

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment essential. While chemotherapy and targeted drugs have ...

Researchers compared intensive chemotherapy with single-agent clofarabine in fit older adults with newly diagnosed AML.